Skip to main navigation Skip to search Skip to main content

Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study

  • Sai Hong Ignatius Ou
  • , Jin Seok Ahn
  • , Luigi De Petris
  • , Ramaswamy Govindan
  • , James Chih Hsin Yang
  • , Brett Hughes
  • , Hervé Lena
  • , Denis Moro-Sibilot
  • , Alessandra Bearz
  • , Santiago Viteri Ramirez
  • , Tarek Mekhail
  • , Alexander Spira
  • , Walter Bordogna
  • , Bogdana Balas
  • , Peter N. Morcos
  • , Annabelle Monnet
  • , Ali Zeaiter
  • , Dong Wan Kim
  • University of California at Irvine
  • Karolinska Institutet
  • Washington University St. Louis
  • National Taiwan University
  • University of Queensland
  • CHU de Rennes
  • CHU de Grenoble
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • USP Institut Universitari Dexeus
  • AdventHealth Orlando
  • Virginia Cancer Specialists
  • F. Hoffmann-La Roche AG
  • Seoul National University

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science